412 related articles for article (PubMed ID: 34063285)
1. CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology.
Kawakita E; Koya D; Kanasaki K
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34063285
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Yang F; Takagaki Y; Yoshitomi Y; Ikeda T; Li J; Kitada M; Kumagai A; Kawakita E; Shi S; Kanasaki K; Koya D
Cancer Res; 2019 Feb; 79(4):735-746. PubMed ID: 30584072
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
4. Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells.
Li S; Fan Y; Kumagai A; Kawakita E; Kitada M; Kanasaki K; Koya D
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31991851
[TBL] [Abstract][Full Text] [Related]
5. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy.
Aytac U; Dang NH
Curr Drug Targets Immune Endocr Metabol Disord; 2004 Mar; 4(1):11-8. PubMed ID: 15032621
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
Gilbert MP; Pratley RE
Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
8. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
9. Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes.
Deacon CF
Front Endocrinol (Lausanne); 2019; 10():80. PubMed ID: 30828317
[TBL] [Abstract][Full Text] [Related]
10. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation.
Jungraithmayr W; De Meester I; Matheeussen V; Baerts L; Arni S; Weder W
Eur J Cardiothorac Surg; 2012 May; 41(5):1166-73. PubMed ID: 22219460
[TBL] [Abstract][Full Text] [Related]
11. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
[TBL] [Abstract][Full Text] [Related]
12. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Bae EJ
Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
[TBL] [Abstract][Full Text] [Related]
13. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
14. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
Campbell RK
Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
Kirby M; Yu DM; O'Connor S; Gorrell MD
Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl Peptidase-4 Is a Pro-Recovery Mediator During Acute Hepatotoxic Damage and Mirrors Severe Shifts in Kupffer Cells.
Duarte N; Coelho I; Holovanchuk D; Inês Almeida J; Penha-Gonçalves C; Paula Macedo M
Hepatol Commun; 2018 Sep; 2(9):1080-1094. PubMed ID: 30202822
[TBL] [Abstract][Full Text] [Related]
17. Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.
Noh Y; Jeon SM; Shin S
Int J Cancer; 2019 Apr; 144(7):1530-1539. PubMed ID: 30229901
[TBL] [Abstract][Full Text] [Related]
18. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
Santamarina M; Carlson CJ
BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
[TBL] [Abstract][Full Text] [Related]
19. Cancer Biology and Prevention in Diabetes.
Srivastava SP; Goodwin JE
Cells; 2020 Jun; 9(6):. PubMed ID: 32498358
[TBL] [Abstract][Full Text] [Related]
20. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
Nauck MA
Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
